FDA Grants Fast Track Status to New Biliary Tract Cancer Immunotherapy, Opamtistomig
Opamtistomig FDA Fast Track granted for first-line biliary tract cancer, nine days after filing. What it means, the data so far and what is unknown.
Tag: PD-L1 4-1BB
Read More